On May 17, 2022 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, reported that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting from June 3–7, 2022 in Chicago, IL (USA) (Press release, OBI Pharma, MAY 17, 2022, View Source [SID1234614782]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These studies will be presented by the lead investigators of OBI Pharma’s first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).

"OBI Pharma is proud to have posters at ASCO (Free ASCO Whitepaper) highlighting the ongoing clinical trials with our first-in-class cancer therapeutics, Adagloxad Simolenin, OBI-999, and OBI-3424. We look forward to providing updates of our current clinical studies, which we believe could offer potential therapeutic benefits for patients whose cancer cells show Globo H or AKR1C3 expression. We are also excited to host an OBI Pharma exhibit booth to meet with investigators and meeting participants" stated Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma.

Poster / Abstract: TPS611
Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.
Session Title: Breast Cancer—Local/Regional/Adjuvant
Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Session Date and Time: Monday, June 6, 2022. 8:00 a.m. – 11:00 a.m. Central Time

Poster / Abstract: 3029
Title: First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Central Time

Poster / Abstract: 3030
Title: Safety, Pharmacokinetics, and Clinical Activity of OBI-3424, an AKR1C3-Activated Prodrug, in Patients with Advanced or Metastatic Solid Tumors: A Phase 1 Dose-Escalation Study
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD,The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Eastern Time

The above poster presentations will be available online at www.obipharma.com on June 6, 2022.

OBI Exhibit Booth # 3144 (McCormick Center, Chicago, IL).
OBI Pharma personnel will be available to discuss our Cancer pipeline under clinical development for ASCO (Free ASCO Whitepaper) meeting attendees only from June 6-8 from 9am to 5 pm CST.

On May 17, 2022 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, reported that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022 (Press release, Gritstone Oncology, MAY 17, 2022, https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-participate-hc-wainwright-global-investment-conference [SID1234614781]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available on-demand beginning Tuesday, May 24 at 7 a.m. ET via the Investors & Media section of Gritstone’s website at View Source An archived replay will be accessible for 30 days following the event.

On May 17, 2022 ERYTECH Pharma reported that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference (Press release, ERYtech Pharma, MAY 17, 2022, https://erytech.com/erytech-to-present-at-the-h-c-wainwright-global-investment-conference/ [SID1234614780]). The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 17, 2022 Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 (Press release, Milestone Pharmaceuticals, MAY 17, 2022, https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-301548550.html [SID1234614777]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone’s website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

On May 17, 2022 Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, reported entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors (Press release, Coeptis Pharmaceuticals, MAY 17, 2022, View Source [SID1234614776]). Among the initial cancer indications under development are pre-clinical programs targeting breast cancer and ovarian cancer. Terms of the deal were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The exclusive option agreement involves the intellectual property rights to three technologies jointly developed in the laboratories of Jason Lohmueller, Ph.D., Assistant Professor of Immunology; Alexander Deiters, Ph.D., Professor of Chemistry; and Olivera Finn, Ph.D., Professor of Immunology: 1) mSA2 affinity-enhanced biotin-binding CAR, 2) universal self-labeling SynNotch and CARs for programable antigen-targeting, and 3) conditional control of universal CAR-T cells through stimulus-reactive adaptors. Per the option agreement, Coeptis paid the University of Pittsburgh a non-refundable fee for the exclusive option to license the patent rights to each of the three technologies. Coeptis has until October 29, 2022, to exercise the options and pay the specified exercise considerations. The option agreement may be extended an additional six months, subject to the agreement of both parties.

"2022 has been a transformational year for Coeptis, and this exclusive option agreement with the University of Pittsburgh provides an unprecedented opportunity to in-license three groundbreaking CAR-T technologies that we believe offer the potential to deliver CAR-T therapies to address both hematologic and solid tumors," said Dave Mehalick, CEO of Coeptis Therapeutics. "We are excited to have the opportunity to collaborate with the University of Pittsburgh to advance these innovative CAR-T technologies, which have the potential to be applied to a wide range of cancers currently underserved by conventional treatment options and first-generation CAR-T therapies, including breast and ovarian cancer."

"CAR-T offers the potential to revolutionize cancer treatment; however, there remain shortcomings with current CAR-T therapies that we believe, if addressed, could enable the technology to be utilized with additional types of cancer, including many solid tumors," said Jason Lohmueller. "Our efforts at the University of Pittsburgh involve three core opportunities: creating a universal CAR-T system that maintains a high-binding affinity, while also offering greater control over toxicity; developing a technology that can target multiple antigens simultaneously; and enabling conditional cell receptor control for systemic control over CAR-T cells. We welcome the opportunity to partner with Coeptis to advance these technologies."

The option agreement with the University of Pittsburgh marks the third material event for Coeptis this quarter and follows the recently announced definitive merger agreement with Bull Horn Holdings Corp. ["Bull Horn"] (Nasdaq: BHSE), a special purpose acquisition company (SPAC) that is anticipated to close in the third quarter of 2022. Additionally, in April, Coeptis entered into a strategic agreement with Statera Biopharma, Inc. that gives Coeptis the right to acquire, subject to satisfaction of certain conditions, Statera’s toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome.